TP53 and plasma cell myeloma: At diagnosis, biallelic events in terms of loss or mutation of TP53 (called double hit myeloma) are detected in 3.7% of patients and represent a crucial marker of adverse prognosis for both PFS and OS, compared to wild-type or mono-allelic inactivation (46).